3 completed. 3 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 3 |
Follow ceritinib: new trials by email Literature Review of ceritinib trials Research Report on ceritinib
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Molecular Profiling of Advanced Soft-tissue Sarcomas Nilotinib, Ceritinib, Capmatinib - Soft Tissue Sarcoma | Phase 3 | Completed | Institut National de la Santé Et de la Recherche Médicale, France | 603 | 2019-10-19 | 2026-04-29 |
| LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer Ceritinib, Pemetrexed, Cisplatin - Non-Small Cell Lung Cancer | Phase 3 | Completed | Novartis Pharmaceuticals | 376 | 2013-07-09 | 2025-01-16 |
| LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib Ceritinib, Pemetrexed, Docetaxel - Non-Small Cell Lung Cancer | Phase 3 | Completed | Novartis Pharmaceuticals | 231 | 2013-06-28 | 2025-02-07 |
Adenocarcinoma of Lung (2) · Carcinoma, Non-Small-Cell Lung (2) · Lung Neoplasms (2) · Neoplasm Metastasis (1) · Sarcoma (1)
Novartis Pharmaceuticals (2) · Institut National de la Santé Et de la Recherche Médicale, France (1)
France (3) · Germany (2) · Ireland (2) · Italy (2) · Japan (2) · Lebanon (2) · Netherlands (2) · Russia (2) · Singapore (2) · South Korea (2) · Spain (2) · Turkey (Türkiye) (2) · United Kingdom (2) · Argentina (1) · Australia (1)
Antoine Italiano (1)
PMID 27130468, PMID 28126333, PMID 28602779, PMID 29474558, PMID 32713836, PMID 34740331
2017 (1)